CN106714795A - 用于治疗尤因家族肿瘤的组合物及方法 - Google Patents

用于治疗尤因家族肿瘤的组合物及方法 Download PDF

Info

Publication number
CN106714795A
CN106714795A CN201680001302.8A CN201680001302A CN106714795A CN 106714795 A CN106714795 A CN 106714795A CN 201680001302 A CN201680001302 A CN 201680001302A CN 106714795 A CN106714795 A CN 106714795A
Authority
CN
China
Prior art keywords
kinase inhibitor
tyrosine kinase
imatinib
biguanide compound
buddhist nun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680001302.8A
Other languages
English (en)
Chinese (zh)
Inventor
赵宏
斯蒂芬·天赐·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital
Original Assignee
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital filed Critical Methodist Hospital
Publication of CN106714795A publication Critical patent/CN106714795A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680001302.8A 2015-08-24 2016-08-22 用于治疗尤因家族肿瘤的组合物及方法 Pending CN106714795A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209197P 2015-08-24 2015-08-24
US62/209,197 2015-08-24
US201562209645P 2015-08-25 2015-08-25
US62/209,645 2015-08-25
PCT/US2016/047984 WO2017035057A1 (en) 2015-08-24 2016-08-22 Compositions and methods for treating ewing family tumors

Publications (1)

Publication Number Publication Date
CN106714795A true CN106714795A (zh) 2017-05-24

Family

ID=58101236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680001302.8A Pending CN106714795A (zh) 2015-08-24 2016-08-22 用于治疗尤因家族肿瘤的组合物及方法

Country Status (7)

Country Link
US (1) US10765675B2 (https=)
EP (1) EP3340978A4 (https=)
JP (1) JP2018525413A (https=)
CN (1) CN106714795A (https=)
CA (1) CA2995642A1 (https=)
TW (1) TW201717926A (https=)
WO (1) WO2017035057A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108034726A (zh) * 2018-01-18 2018-05-15 四川大学华西医院 检测mlh1表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022093789A1 (en) * 2020-10-27 2022-05-05 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of apex, alone and in combination with other cancer drugs to inhibit growth of cancer cells
WO2025097033A1 (en) * 2023-11-01 2025-05-08 City Of Hope Metformin combination therapy for use in cancer treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089034A2 (en) * 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
US20090227464A1 (en) * 2003-07-01 2009-09-10 Smadar Avigad Prognosis determination in ewing sarcoma patients by means of genetic profiling
US20130035329A1 (en) * 2009-12-09 2013-02-07 Saunders Jeffrey O Therapeutically active compositions and their methods of use
US20130183281A1 (en) * 2009-10-21 2013-07-18 Shin-San Michael Su Methods and compositons for cell-proliferation-related disorders
WO2015013579A1 (en) * 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227464A1 (en) * 2003-07-01 2009-09-10 Smadar Avigad Prognosis determination in ewing sarcoma patients by means of genetic profiling
WO2008089034A2 (en) * 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
US20130183281A1 (en) * 2009-10-21 2013-07-18 Shin-San Michael Su Methods and compositons for cell-proliferation-related disorders
US20130035329A1 (en) * 2009-12-09 2013-02-07 Saunders Jeffrey O Therapeutically active compositions and their methods of use
WO2015013579A1 (en) * 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOSEPH CHAO等: "Phase II Clinical Trial of Imatinib Mesylate in Therapy of KIT and/or PDGFRα-expressing Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors", 《ANTICANCER RESEARCH》 *
R.CURVELLO 等: "P03.07METFORMIN PROMOTES CANCER CELLS DEATH, INHIBITS PGP EXPRESSION AND SENSITIZE MDR LEUKEMIC CELLS TO THE EFFECTS OF IMATINIB MESYLATE", 《ANNALS OF ONCOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108034726A (zh) * 2018-01-18 2018-05-15 四川大学华西医院 检测mlh1表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途
CN108034726B (zh) * 2018-01-18 2021-07-30 四川大学华西医院 检测mlh1表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途

Also Published As

Publication number Publication date
CA2995642A1 (en) 2017-03-02
JP2018525413A (ja) 2018-09-06
US20180243299A1 (en) 2018-08-30
EP3340978A1 (en) 2018-07-04
US10765675B2 (en) 2020-09-08
TW201717926A (zh) 2017-06-01
WO2017035057A1 (en) 2017-03-02
EP3340978A4 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
RU2480211C2 (ru) Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
JP7367910B2 (ja) がんの処置
Mukherjee et al. Role of chemotherapeutic drugs in immunomodulation of cancer
CN110573166B (zh) 用于癌症治疗的吉西他滨衍生物
TR201806642T4 (tr) Kanser tedavileri.
KR20240110659A (ko) Ｍｄｍ２ 억제제의 간헐적 투여
CN115769077A (zh) 用于治疗癌症的方法和组合物
JP2021505548A (ja) 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用
WO2019229259A1 (en) Materials and methods for monitoring the development of resistance of cancers to treatment
KR20180064540A (ko) 암 치료를 위한 mdm2 억제제의 투여 요법
JP2021169534A (ja) 化学療法の改善
CN113631193A (zh) 用于治疗癌症的金属螯合剂组合疗法
JP2013542965A (ja) 腫瘍の治療方法
CN106714795A (zh) 用于治疗尤因家族肿瘤的组合物及方法
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
US9901594B2 (en) Pharmaceutical composition and uses thereof
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
EP4479042A1 (en) Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
WO2019216360A1 (ja) 前立腺がんの予防又は治療剤
KR20140035974A (ko) 종양 질환 치료를 위한 약제 조성물
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
US20180235936A1 (en) Cancer treatment methods
JP2025509248A (ja) 化学療法薬により誘発される腎毒性の処置のための方法
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
Markmam Berek & Hacker's gynecologic oncology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170524

WD01 Invention patent application deemed withdrawn after publication